查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1392003

Calcineurin酶抑制劑市場：按藥物類型、按給藥途徑、按適應症（預防器官移植排斥、自體免疫疾病、眼科疾病）、配銷通路、按最終用戶、按地區

Calcineurin Inhibitor Market, By Drug Type, By Route of Administration, By Indication (Organ Transplant Rejection Prevention, Autoimmune Diseases, Ophthalmic Diseases, By Distribution Channel, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計2023年全球Calcineurin酶抑制劑市場規模為100.7億美元，2030年將達206.4億美元，2023-2030年預測期間年複合成長率為10.8%。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 100.7億美元
實績資料 2018-2021 預測期 2023-2030
預測期年複合成長率 10.80% 2030年市場規模預測 206.4億美元
圖 1. 2023 年Calcineurin抑制劑的全球市場佔有率(%)（按地區）
鈣調神經磷酸酶抑制劑市場-IMG1

Calcineurin抑制劑是一種免疫抑制劑。這些藥物透過抑制免疫系統活動發揮作用，從而防止免疫系統攻擊移植器官。它常用於器官移植，特別是腎臟、心臟和肝臟移植。Calcineurin酶抑制劑主要有兩種類型：環孢素和他克莫司。所有這些藥物都已被證明可以有效預防器官排斥，但它們也可能產生嚴重的副作用，包括腎損傷、高血壓以及感染疾病和癌症風險增加。由於器官移植和自體免疫疾病的盛行率增加，預計Calcineurin酶抑制劑的全球市場將會成長。該市場也受到新藥開拓和現有藥物適應症擴大的推動。然而，這些藥物的副作用和移植的高成本可能會阻礙市場成長。全球Calcineurin抑制劑市場的主要企業包括諾華公司、安斯泰來製藥公司、艾爾建公司和輝瑞公司。這些公司專注於開發新型和改進的Calcineurin抑制劑的研發活動。按地區分類，北美在Calcineurin抑制劑市場中佔有最大佔有率，其次是歐洲。這是由於這些地區器官移植和自體免疫疾病的高發生率。由於該地區醫療支出的增加和器官移植意識的增強，預計亞太市場將顯著成長。

市場動態：

自體自體免疫疾病和器官移植病例的增加預計將在不久的將來推動全球Calcineurin酶抑制劑市場的成長。一個主要促進因素是對Calcineurin抑制劑的需求不斷增加，以防止移植器官的排斥。他克莫司是一種Calcineurin抑制劑，是一種用於治療器官移植患者的免疫抑制劑，可降低人體排斥移植器官的能力。

然而，與Calcineurin抑制劑相關的副作用，例如皮膚刺激和胃腸道疾病，可能會阻礙市場成長。此外，與給藥藥物給藥相關的風險（例如腎毒性和肝毒性）預計也將在不久的將來阻礙市場成長。

本研究的主要特點

  • 本報告對全球Calcineurin酶抑制劑市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR%）。
  • 它還揭示了各個細分市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
  • 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
  • 它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球Calcineurin抑制劑市場的主要企業。
  • 該報告的見解將使行銷人員和經營團隊負責人就未來的產品發布、類型升級、市場擴張和行銷策略做出資訊的決策。
  • 全球Calcineurin酶抑制劑市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 透過用於分析全球Calcineurin酶抑制劑市場的各種策略矩陣，將促進相關人員的決策。

目錄

第1章 研究目的與假設

  • 研究目標
  • 假設
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章市場動態、法規及趨勢分析

  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/核准
  • PEST分析
  • 波特的分析
  • 併購場景

第4章全球Calcineurin酶抑制劑市場－冠狀病毒（COVID-19）大流行的影響

  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 供需面分析
  • 經濟影響

第5章全球Calcineurin酶抑制劑市場，依藥物類型，2018-2030

  • 介紹
  • 環孢素
  • 他克莫司
  • 吡美莫司
  • 沃羅孢素
  • 其他

第6章全球Calcineurin抑制劑市場，依給藥途徑，2018-2030

  • 介紹
  • 口服
  • 局部的
  • 靜脈

第7章 全球Calcineurin酶抑制劑市場，依適應症分類，2018-2030 年

  • 介紹
  • 器官移植排斥反應的預防
  • 自體免疫疾病
  • 眼科疾病
  • 其他皮膚病

第8章全球Calcineurin酶抑制劑市場，依配銷通路，2018-2030

  • 介紹
  • 醫院藥房
  • 零售藥房
  • 線上藥房

第 9 章全球Calcineurin酶抑制劑市場，按最終用戶分類，2018-2030 年

  • 介紹
  • 醫院
  • 專科診所
  • 皮膚科中心
  • 移植中心

第10章全球Calcineurin酶抑制劑市場，按地區，2018-2030

  • 介紹
  • 北美洲
  • 美國
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 歐洲其他地區
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 東南亞國協
  • 其他亞太地區
  • 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東地區
  • 非洲
  • 南非
  • 北非
  • 中部非洲

第11章競爭形勢

  • Novartis AG
  • Amgen
  • F.Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Incyte Corporation
  • Chiesi Farmaceutici SpA
  • Astellas Pharma Inc.
  • Sanofi SA
  • Bristol Myers Squibb Company
  • Mylan NV
  • Reddy's Laboratories Ltd.
  • Senju Pharmaceutical Co. Ltd
  • Abbott
  • Lupin Limited
  • Vibcare Pharma Pvt. Ltd.

第12章 章節

  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI5848

Global calcineurin inhibitor market size is expected to be valued at US$ 10.07 Bn in 2023, and is expected to reach US$ 20.64 Bn by 2030, exhibiting a CAGR of 10.8% during the forecast period of 2023 to 2030.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 10.07 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 10.80% 2030 Value Projection: US$ 20.64 Bn
Figure 1. Global Calcineurin Inhibitor Market Share (%), By Region, 2023
Calcineurin Inhibitor Market - IMG1

Calcineurin inhibitors are a type of immunosuppressant. These drugs work by suppressing the activity of the immune system to prevent it from attacking the transplanted organ. They are commonly used in organ transplantation, especially kidney, heart, and liver transplants. There are two main types of calcineurin inhibitors: cyclosporine and tacrolimus. Both of these drugs have been proven to be effective in preventing organ rejection, but they can also have serious side effects, including kidney damage, high blood pressure, and an increased risk of infections and cancer. The global calcineurin inhibitors market is expected to grow due to the increasing prevalence of organ transplantation and autoimmune diseases. The market is also driven by the development of new drugs and the expansion of indications for existing drugs. However, the market growth may be hindered by the side effects of these drugs and the high cost of transplantation. Key players in the global calcineurin inhibitors market include Novartis AG, Astellas Pharma Inc., Allergan, Inc., and Pfizer Inc. These companies are focusing on research and development activities to develop new and improved calcineurin inhibitors. In terms of geography, North America holds the largest share of the calcineurin inhibitors market, followed by Europe. This is due to the high prevalence of organ transplantation and autoimmune diseases in these regions. The market in Asia Pacific is expected to grow at a significant rate due to the increasing healthcare expenditure and the growing awareness about organ transplantation in this region.

Market Dynamics:

Increasing cases of autoimmune diseases and organ transplantation is expected to drive growth of the global calcineurin inhibitor market in the near future. Increasing demand for the calcineurin inhibitors to prevent rejection of transplanted organs is the major driving factor. For instance, in December 2020, Biocon, an innovation-led global biopharmaceutical company, announced the launch of Tacrolimus capsules in the U.S. Tacrolimus is a calcineurin inhibitor, an immunosuppressant used in the treatment of organ transplant patients that reduces the body's ability to reject a transplanted organ.

However, side effects associated with calcineurin inhibitors such as skin irritation and gastrointestinal disturbances may hamper the market growth. Moreover, risks connected with overdosing of the orally administered drugs such as nephrotoxicity and hepatotoxicity are also expected to hamper the market growth in the near future.

Key features of the study:

  • This report provides in-depth analysis of the global calcineurin inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global calcineurin inhibitor market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Novartis AG, Amgen, F. Hoffmann-La Roche Ltd, Pfizer Inc., Incyte Corporation, Chiesi Farmaceutici S.p.A., Astellas Pharma Inc., Sanofi SA, Bristol Myers Squibb Company, Mylan N.V., Dr. Reddy's Laboratories Ltd., Senju Pharmaceutical Co. Ltd, Abbott, Lupin Limited, and Vibcare Pharma Pvt. Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global calcineurin inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcineurin inhibitor market

Detailed Segmentation:

  • Global Calcineurin Inhibitor Market, By Drug Type:
    • Cyclosporine
    • Tacrolimus
    • Pimecrolimus
    • Voclosporin
    • Others
  • Global Calcineurin Inhibitor Market, By Route of Administration:
    • Oral
    • Topical
    • Intravenous
  • Global Calcineurin Inhibitor Market, By Indication:
    • Organ Transplant Rejection Prevention
    • Autoimmune Diseases
    • Ophthalmic Diseases
    • Other Dermatological Conditions
  • Global Calcineurin Inhibitor Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Calcineurin Inhibitor Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Dermatology Centers
    • Transplant Centers
  • Global Calcineurin Inhibitor Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Novartis AG
    • Amgen
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • Incyte Corporation
    • Chiesi Farmaceutici S.p.A.
    • Astellas Pharma Inc.
    • Sanofi SA
    • Bristol Myers Squibb Company
    • Mylan N.V.
    • Dr. Reddy's Laboratories Ltd.
    • Senju Pharmaceutical Co. Ltd
    • Abbott
    • Lupin Limited
    • Vibcare Pharma Pvt. Ltd.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Calcineurin Inhibitor, By Drug Type
    • Market Calcineurin Inhibitor, By Route of Administration
    • Market Calcineurin Inhibitor, By Indication
    • Market Calcineurin Inhibitor, By Distribution Channel
    • Market Calcineurin Inhibitor, By End User
    • Market Calcineurin Inhibitor, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Calcineurin Inhibitor Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Calcineurin Inhibitor Market, By Drug Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2023 - 2030
    • Segment Trends
  • Cyclosporine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Tacrolimus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Pimecrolimus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Voclosporin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Calcineurin Inhibitor Market, By Route of Administration, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global Calcineurin Inhibitor Market, By Indication, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Organ Transplant Rejection Prevention
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Autoimmune Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Ophthalmic Diseases
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Other Dermatological Conditions
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Calcineurin Inhibitor Market, By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

9. Global Calcineurin Inhibitor Market, By End User, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Dermatology Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Transplant Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

10. Global Calcineurin Inhibitor Market, By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019 - 2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
  • South Africa
  • North Africa
  • Central Africa

11. Competitive Landscape

  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen
  • F.Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Incyte Corporation
  • Chiesi Farmaceutici S.p.A.
  • Astellas Pharma Inc.
  • Sanofi SA
  • Bristol Myers Squibb Company
  • Mylan N.V.
  • Reddy's Laboratories Ltd.
  • Senju Pharmaceutical Co. Ltd
  • Abbott
  • Lupin Limited
  • Vibcare Pharma Pvt. Ltd.
  • Analyst Views

12. Section

  • Research Methodology
  • About us